Introduction An example of patient’s own experience of being used as an interface between sponsors and participants of clinical trials. Taking place both in rare diseases with EURORDIS and...
Introduction A collaboration of the CML Advocates Network / Leukaemia Patient Advocates Foundation with a major pharmaceutical company regarding the use of a medicine in Phase III trials (adult...
Transcription My name is Dimitrios Athanasiou. I am a parent of a child with Duchenne muscular dystrophy. I am a full-time patient advocate for Duchenne and rare diseases,...
Transcription My name is Tetiana Zamorska, I’m coming from Ukraine. I live in the capitol of Ukraine, Kiev. My son was born with a rare skin disorder called,...
Galenic formulation deals with the principles of preparing and compounding active ingredients into ready-to-use medicines in order to optimise their absorption by the body.
Risk factors are those factors linked to poor health, disability, disease, or death. Generally, risk factors can be classified as behavioural, physiological, demographic, environmental, or genetic. Reducing exposure to...
Phase II clinical studies, or proof of concept studies, begin to test the effect of a medicine on the target disease in humans. These studies are usually run as...
Developing medicines for children is important, but requires special measures to be taken during clinical development in order to shield children from undue risk.
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.
